C07C 229/64
The carbon skeleton being further substituted by singly-bound oxygen atoms
Official title: the carbon skeleton being further substituted by singly-bound oxygen atoms
C07C229/64 (The carbon skeleton being further substituted by singly-bound oxygen atoms) appears on 105 US grants and 96 published applications in this corpus.
Search patents in C07C- Granted patents
- 105
- Published applications
- 96
- Assignees
- 98
- Inventors
- 428
- Latest grant
- 9 Sep 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1977 | 1 | 0 |
| 1978 | 0 | 0 |
| 1979 | 0 | 0 |
| 1980 | 0 | 0 |
| 1981 | 1 | 0 |
| 1982 | 0 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 1 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 2 | 0 |
| 1992 | 1 | 0 |
| 1993 | 2 | 0 |
| 1994 | 3 | 0 |
| 1995 | 3 | 0 |
| 1996 | 3 | 0 |
| 1997 | 5 | 0 |
| 1998 | 1 | 0 |
| 1999 | 4 | 0 |
| 2000 | 5 | 0 |
| 2001 | 0 | 0 |
| 2002 | 2 | 0 |
| 2003 | 2 | 6 |
| 2004 | 2 | 4 |
| 2005 | 7 | 5 |
| 2006 | 1 | 5 |
| 2007 | 3 | 2 |
| 2008 | 5 | 6 |
| 2009 | 2 | 4 |
| 2010 | 3 | 5 |
| 2011 | 3 | 9 |
| 2012 | 6 | 5 |
| 2013 | 6 | 7 |
| 2014 | 4 | 5 |
| 2015 | 4 | 2 |
| 2016 | 3 | 4 |
| 2017 | 3 | 3 |
| 2018 | 3 | 4 |
| 2019 | 3 | 2 |
| 2020 | 1 | 2 |
| 2021 | 2 | 5 |
| 2022 | 3 | 2 |
| 2023 | 1 | 1 |
| 2024 | 1 | 3 |
| 2025 | 3 | 2 |
| 2026 | 0 | 3 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Processes and intermediates for preparing MCL1 inhibitors9 Sep 2025US 12,410,146 B2Gilead Sciences, Inc.
- Anthranilic acid-based compound, and Pin1 inhibitor, therapeutic agent for inflammatory diseases and therapeutic agent for cancer that use the same15 Jul 2025US 12,357,626 B2Amenis Bioscience, Inc.
- EBNA1 inhibitors and their method of use25 Mar 2025US 12,258,314 B2The Wistar Institute of Anatomy and Biology
- Pharmaceutically acceptable salts of [3-(4- {2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1H-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine30 Jan 2024US 11,883,383 B2vTv Therapeutics LLC
- Processes and intermediates for preparing MCL1 inhibitors19 Sep 2023US 11,760,736 B2Gilead Sciences, Inc.
- Therapeutic compounds1 Oct 2026US 2026/0297016 A1Regents of the University of Minnesota
- Substituted 3-fluorobenzenepropanoate compound and preparation method therefor, pharmaceutical composition thereof, and use thereof14 May 2026US 2026/0132115 A1Tianjin Gudui Bio-Pharm Co., Ltd.
- Processes and intermediates for preparing mcl1 inhibitors26 Feb 2026US 2026/0055068 A1Gilead Sciences, Inc.
- Fragrance and flavor compositions comprising benzene derivatives24 Jul 2025US 2025/0236810 A1
- Salt crystals24 Apr 2025US 2025/0129087 A1Intra-Cellular Therapies, Inc.
Most cited
By later US patents
- Amyloid binding nitrogen-linked compounds for the antemortem diagnosis of alzheimer's disease, in vivo imaging and prevention of amyloid deposits87US 6,417,178 B1University of Pittsburgh · 2002
- Anthranilic acid derivatives78US 5,716,993 AEisai Co., Ltd. · 1998
- Catechol carboxylic acids67US 5,025,036 AHoffmann-La Roche Inc. · 1991
- Container assembly for intravaginal fertilization and culture and embryo transfer and method of intravaginal fertilization and culture employing such a container54US 6,050,935 ABiofertec · 2000
- Substituted quinazolinones for treating neurological conditions36US 8,084,459 B2Prana Biotechnology Limited · 2011